DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma.

by Anthony B Eason, Sang-Hoon Sin, Mohsin Shah, Hong Yuan, Douglas J Phillips, Miriam Droste, Abdijapar Shamshiev, Dirk P Dittmer
Published 2020-01-01